Item

Comparative oncology of TP53: Leveraging elephants' cancer resistance for humans

Barton, Jocelyn
Citations
Altmetric:
License
License
Abstract
The TP53 gene encodes the p53 protein, essential for DNA repair and tumor suppression. While humans have one copy of TP53, elephants have 20, contributing to their remarkably low cancer rates. TP53 mutations occur in 50% of cancers, yet no targeted therapies exist. Joshua Schiffman, CEO of Peel Therapeutics, observed rapid cell destruction by adding one elephant TP53 copy to human osteosarcoma cells. MDM2, an inhibitory protein, binds to TP53 and marks it for destruction, but elephants have evolved to counteract this. Peel Therapeutics is developing TP53-based therapies in preclinical trials by restoring p53 folding and blocking MDM2 binding.
Description
Date
2025-05-29
Student Status
Undergraduate
Journal Title
Journal ISSN
Volume Title
Type of presentation
Poster Presentation
Collections
UVM Student Research Conference
Show all metadata
Research Projects
Organizational Units
Journal Issue
Citation
URI
https://hdl.handle.net/20.500.14849/8914
DOI
Advisor(s)
Melissa Pespeni
Department
Program/Major
Neuroscience
College/School
College of Arts and Sciences
Organization
Research Category
Life Sciences
Embedded videos